GEN Exclusives

More »

GEN Poll

More »
Jun 08, 2009

Reimbursing Molecular Diagnostics

Molecular diagnostics is one of the fastest growing areas of biotechnology product development. Once firmly rooted in the research side of the business, DNA testing is quickly making headway in the clinical arena in, for example, prenatal, tissue typing, and inherited disease applications. However, some industry analysts maintain that concern over reimbursement is acting as a roadblock to an even greater penetration of molecular diagnostic tests in the medical field. Do you agree?

Is insufficient reimbursement holding molecular diagnostic tests back from reaching the clinic?


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Global Antibiotic Resistance

Do you find the association of a country’s antibiotic resistance being tied to its degree of corruption rather than its wealth surprising?

More »